SCHEMBL334064

SCHEMBL334064

CCN(CC)c1ccc(-n2c(CC(=O)O)c(C(=O)O)c3cc(Oc4cccc(Cl)c4)ccc32)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP14 P54578 1/20 0.43
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
PTGES O14684 1/20 0.40
KDM4E B2RXH2 1/20 0.39
HIF1A Q16665 1/20 0.39
FFAR1 O14842 1/20 0.38
PPARG P37231 5/20 0.38
ALDH1A1 P00352 3/20 0.37
MAPT P10636 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
NPSR1 Q6W5P4 1/20 0.37
PPARA Q07869 1/20 0.36
LMNA P02545 2/20 0.36
TSHR P16473 2/20 0.36
HTT P42858 1/20 0.36
TP53 P04637 1/20 0.36
MAPK1 P28482 1/20 0.35
ATM Q13315 1/20 0.35
NPY1R P25929 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL332540 0.92 USP14 (0.47) USP14MEN1KMT2APTGESKDM4E
SCHEMBL333835 0.88 KDM4E (0.47) USP14MEN1KMT2APTGESKDM4E
SCHEMBL334342 0.86 USP14 (0.45) USP14MEN1KMT2APTGESKDM4E
SCHEMBL333497 0.85 USP14 (0.44) USP14MEN1KMT2APTGESKDM4E
SCHEMBL503756 0.85 USP14 (0.45) USP14MEN1KMT2APTGESKDM4E
SCHEMBL333584 0.84 PTGES (0.49) USP14MEN1KMT2APTGESMAPT
SCHEMBL333566 0.84 PPARG (0.41) USP14MEN1KMT2AKDM4EPPARG
SCHEMBL334181 0.84 PPARG (0.43) MEN1KMT2AKDM4EPPARGPPARA
SCHEMBL333845 0.84 PPARG (0.42) USP14PTGESKDM4EHIF1AFFAR1
SCHEMBL333480 0.80 MEN1 (0.40) MEN1KMT2AKDM4EPPARGALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097623-B2 1-Aryl-or heteroaryl-3-aryl-or heteroarylindole-2-carboxylic acids or esters: e.g., 5-(4-tert-Butylphenyl)-1,3-bis(4-isopropoxyphenyl)-indole-2-carboxylic acid; inhibition of the activity of microsomal prostaglandin E synthase-1, leukotriene C4 and/or 5-lipoxygenase-activating protein; analgesics BIOLIPOX AB (SE) 2012-01-17 US disclosed
EP-1841735-B1 INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION BIOLIPOX AB (SE) 2011-03-09 EP disclosed
US-20090076004-A1 Indoles Useful in the Treatment of Inflammation BIOLIPOX AB (SE) 2009-03-19 US disclosed
CN-101142185-A Indoles useful in the treatment of inflammation BIOLIPOX AB (SE) 2008-03-12 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076004-A1 Indoles Useful in the Treatment of Inflammation IDO1, IDO2, AREG USP14 3873/4885MEN1 2066/4885KMT2A 3484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.